The mu opioid receptor (MOR; OPRM1) belongs to the Class A (rhodopsin family) Gi/o coupled family of G protein coupled receptors (GPCRs) and functions to reduce neuronal excitability primarily by increasing potassium conductance and inhibiting voltage-gated calcium channels (Law et al., 2000; Williams et al., 2001) . The opioid system is usually described within the context of drug abuse and analgesic drug action, however the normal physiological role of the opioid system is to regulate pain sensitivity, endocrine functioning, gut motility and smooth muscle tone in response to physiological stressors (Drolet et al., 2001; Lopez et al., 1999) . The regulation of mu opioid signaling is a dynamic and complex process (Law et al., 2000) . A primary desensitization mechanism involving G-protein receptor kinase (GRK) and β-arrestin dependent internalization through cytoplasmic serine/threonine phosphorylation has been well described (Celver et al., 2001; Celver et al., 2004; Williams et al., 2001 ).
In addition, MOR contains four highly conserved cytoplasmic tyrosine residues (Thompson et al., 1993) , and tyrosine kinase mediated mechanisms regulating MOR signaling have also been described (Zhang et al., 2009; McLaughlin and Chavkin, 2001) . Tyrosine phosphorylation may influence MOR trafficking and signaling (Pak et al., 1999) , consistent with the effects of tyrosine phosphorylation on internalization and signaling of the delta and kappa opioid receptors (Kramer et al., 2000; Appleyard et al., 2000) . A recent study by Law and colleagues showed that tyrosine phosphorylation of MOR at Y166 and Y336 controlled the switch from inhibition to stimulation of adenylyl cyclase following prolonged agonist application (Zhang et al., 2009) . A prior receptor mutagenesis study from our group also showed that tyrosine phosphorylation of MOR regulates agonist coupling efficiency following heterologous gene expression of MOR in Xenopus oocytes (McLaughlin and Chavkin, 2001) . The latter study demonstrated that the increase in K ir 3-mediated potassium conductance evoked by mu agonist stimulation could be strongly suppressed by MOR tyrosine phosphorylation; this could be blocked by mutation of Y166 and Y106 to phenylalanines, whereas mutation of Y96 or Y336 had no effect on signaling (McLaughlin and Chavkin, 2001 ). Inhibition of the high basal level of tyrosine kinase activity and stimulation of tyrosine phosphatases in these cells robustly increased mu opioid activation of K ir 3 induced by wild type MOR, but not MOR(Y106F) or MOR(Y166F) expressing cells (McLaughlin and Chavkin, 2001 suggested that tyrosine phosphorylation of MOR at the 106 or 166 sites could reduce coupling efficiency, but the underlying mechanism and relevance to signal transduction in mammalian cells was not evident.
Tyrosine 166 is part of the highly conserved DRY motif among class A GPCRs (Rovati et al., 2007) . The DRY motif, located at the boundary of transmembrane 3 and intracellular loop 2, is thought to be important for regulating conformational states of the GPCR and G-protein activation. Molecular modeling of class A GPCRs suggests that in the inactive conformation the arginine residue (D3.50) forms a double salt bridge with its neighboring aspartate (R3.49) and a charged residue on helix 6 (Rovati et al., 2007) . Computational methods predict that agonist-induced conformational changes involve breaking the ionic lock between D3.50 and a glutamic acid on helix 6 (E6.30) (Bhattacharya et al., 2008a; Bhattacharya et al., 2008b) . Mutation of the aspartic acid in many class A GPCRs, including D(3.49) in MOR leads to constitutive, agonist-independent activation of the receptor (Li et al., 2001b) . Other research has shown that in some GPCRs non-conservative mutations lead to a loss of G-protein coupling (Rovati et al., 2007) .
To better understand the role of phosphorylation of the tyrosine in the DRY motif, we generated a Mutagenesis of MOR and transfection of HEK293 cells. Mutation of the mu-opioid receptor of tyrosine 166 to a phenylalanine was done as previously described (McLaughlin and Chavkin, 2001 ).
Stable transfections of the MOR-GFP and MOR(Y166F)-GFP constructs into HEK293 cells were obtained as described previously (Celver et al., 2004) .
Antibody generation and affinity purification. A polypeptide-containing residues 158-177 (KTMSVDRpYIAVCHPVKALD) of the mu-opioid receptor phosphorylated at tyrosine-166 was generated by PeptidoGenic Research & Co., Inc (Livermore, CA). Polyclonal antibody generation and affinity purification using 2-5 μ mol of MOR-Y166p peptide was done as described previously for other phosphopeptide antibodies (Ippolito et al., 2005) . Sera aliquots (4 ml) were added to the peptide conjugated Sepharose beads and incubated for 72 hrs at 4°C with gentle rocking. Unbound protein was washed off the beads using 20 ml of Tris (50 mM, pH 7.4) containing NaCl (150 mM) and NaN 3 (0.02%).
Antibody was eluted with 5 ml MgCl 2 (5 M) in Tris/NaCl and concentrated using a Bedford, MA) . Antibody aliquots were stored at -20°C in 30% glycerol. Protein concentrations were determined by the by bicinchoninic assay (BCA) (Pierce, Rockford, IL). HEK293 membrane homogenates as previously described (Carroll et al., 2005) . Briefly, cells were treated with vehicle, DAMGO (1 μ M), EGF (50 ng/ml), or DAMGO + EGF at specified time points.
ELISA
After treatment cells were washed 2x with PBS. Cells were scraped into 2 ml membrane buffer containing (300 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF, 1x protease and 1x phosphatase inhibitor cocktails (Calbiochem). Cells were then homogenized with a Polytron homogenizer for 2 x 10 sec pulses. Homogenates were centrifuged at 30,000 xg at 4°C for 20 min. Supernatant was discarded and pellet was washed in membrane buffer, rehomogenized, and recentrifuged one more time before freezing the pellet at -80°C until use. In western blot experiments the remaining membrane pellet was resuspended in a buffer containing (in mM) 150 NaCl, 1 CaCl 2 , 1 MgCl 2 , 10% glycerol and 1% n- hr at room temperature, washed 3x 5 min in TBST and 2x 5 minutes in TBS. Immunoblots were scanned using the Odyssey Infrared imaging system and band intensities were measured as described previously (Bruchas et al., 2006) . 
Results
A phosphopeptide containing residues 159-177 of the MOR sequence phosphorylated at tyrosine 166 was used to generate an affinity-purified polyclonal antibody (Fig. 1A) . The resulting reagent demonstrated a high degree of selectivity for the phosphopeptide compared with the unphosphorylated version in the Elisa assay (Fig. 1B) . Using membrane proteins isolated from HEK293 cells stably expressing a GFP-tagged μ -opioid receptor (MOR-GFP), we found that basal MOR-Y166p-ir was low as visualized by western blot ( Fig. 2A) . Treatment of the cells with hydrogen peroxide (H 2 O 2 , 4.5 mM) for 15 min did not increase MOR-Y166p-ir ( Fig. 2A, lane 2) . This result was surprising since H 2 O 2 is a known activator of tyrosine kinases and inhibitor of tyrosine phosphatases that leads to an overall increase in tyrosine phosphorylation within the cell (Takano et al., 2002; Thakali et al., 2007) . Similarly, treatment with the MOR-specific agonist, DAMGO (1 μ M), for 30 min alone did not increase MORY166p-ir ( Fig. 2A, lane 3) . In contrast, 30 min treatment with 1 μ M DAMGO followed by subsequent cotreatment with 4.5 mM H 2 O 2 for 15 min caused a significant increase in MOR-Y166p-ir ( Fig. 2A, lane 4) .
The apparent molecular weight of the immunoreactive band was approximately 82 kDa (supplemental Fig. 1 ), which is consistent with prior determinations of MOR mobility in western blots (Petraschka et al., 2007) . The MOR-Y166p-ir protein band showed the same mobility as the band detected by anti-mouse GFP and peroxide treatment did not affect MOR-GFP protein expression. Quantification of replicate images indicate that the MOR-Y166p-ir band intensity significantly increased 3.38 + 0.56 fold (n= 5) following combined DAMGO-H 2 O 2 treatment, but was not significantly affected by treatment with either DAMGO or H 2 O 2 alone ( Fig. 2A, left) .
Specificity of the MOR-Y166p antibody was assessed using HEK293 cells transfected with the MOR-Y166F-GFP, having tyrosine-166 mutated to phenylalanine (McLaughlin and Chavkin, 2001 ).
Although these cells were shown to express equivalent amounts of MOR, treatment with DAMGO and H 2 O 2 alone or in combination failed to significantly increase MOR-Y166p-ir (Fig. 2B) . Similarly, untransfected HEK293 cells did not show MOR-Y166p-ir (Fig. 2C) . These results suggest that the This article has not been copyedited and formatted. The final version may differ from this version. tyrosine-166 residue is occluded in the basal state, and that agonist activation by DAMGO unmasks the phosphorylation site.
We confirmed these results using confocal microscopy of HEK293 cells stably expressing MOR-GFP. Treatment with 1 µM DAMGO for 30 min alone induced receptor internalization (green), as shown by the comparison between the cell surface labeling (Fig. 3A) and cytosolic localization of the green fluorescence in panel B. Treatment with DAMGO alone did not increase MOR-Y166p-ir (red) (Fig. 3B ).
In contrast, co-treatment with 1 µM DAMGO and H 2 O 2 caused both internalization of MOR-GFP and a significant increase in MOR-Y166p-ir (Fig. 3C ). HEK293 cells stably expressing MOR(Y166F)-GFP show equivalent plasma membrane localization of GFP ( Fig. 3D ) and robust internalization following DAMGO treatment (Fig. 3E) . Previous reports have shown that mutation of the aspartate residue, a part of the DRY triad, resulted in agonist-independent internalization of MOR (Li et al., 2001a; Li et al., 2001b) . However, mutation of the tyrosine-166 residue did not promote agonist-independent internalization of MOR(Y166F)-GFP (Fig. 3D ). Neither treatment with 1 µM DAMGO alone or with 4.5 mM H 2 O 2 , increased MOR-Y166p-ir in MOR(Y166F)-GFP expressing cells (Fig. 3E,F) . Quantification of replicate images confirmed that MOR-Y166p-ir was significantly increased by combined DAMGO and H 2 O 2 treatment of cells expressing MOR-GFP, but not cells expressing MOR(Y166F)-GFP (Fig. 3G ).
These results further support the conclusion that the antibody generated is able to detect phosphorylation of tyrosine-166 and that prior activation of the mu-opioid receptor is required for this phosphorylation event to occur.
Peroxide treatment is a fairly nonselective tyrosine kinase activator and activates several different tyrosine kinase cascades (Klann & Thiels, 1999) . HEK293 cells endogenously express the EGF-receptor tyrosine kinase system (Kramer et al., 2002) , and other groups have shown that EGF receptor and MOR interact (Belcheva et al., 2003; Chen et al., 2008) . We next asked if activation of the EGF receptor could also increase MOR-Y166p-ir. Treatment of HEK293 cells stably expressing MOR-GFP with 50 ng/ml EGF alone for 5 min did not lead to tyrosine phosphorylation of the receptor (Fig. 4B, row 2) . However, increase in MOR-Y166p-ir that appeared to co-localize with the green fluorescence of the receptor (Fig.   4C , row 2 and 4). Quantification of replicate images confirmed that EGF alone did not significantly increase MOR-Y166p-ir, whereas co-treatment with DAMGO and EGF did increase staining by 1.72 + 0.12 fold (n= 6) (Fig. 4D) .
These results support the hypothesis that agonist-induced activation of MOR by DAMGO leads to a conformational change that allows access of the receptor tyrosine kinase initiated cascade to the tyrosine 166 residue; however, the identity of the kinase directly responsible for the increase in (Fig. 6B) . These results suggest that activation of Src may be responsible for the increased MOR-Y166p-ir.
As previously discussed, the DRY motif has been suggested to have a significant role in agonistdependent activation of G proteins (Rovati et al., 2007) . To assess the effects of tyrosine-166 phosphorylation on G-protein activation by MOR, we used the [ 35 S]GTPγS binding assay to measure changes in DAMGO efficacy (Harrison and Traynor, 2003 was not evident in untransfected cells (Fig. 7A) 
Discussion
In this study we investigated the mechanism and effects of phosphorylation of MOR-tyrosine 166, a residue previously found to be important in regulating receptor efficacy (McLaughlin and Chavkin, 2001 ). To elucidate the mechanism of receptor phosphorylation, we generated and characterized an affinity-purified antipeptide antibody selective for tyrosine-166 phosphorylation: MOR-Y166p. We found that increases in MOR-Y166p-ir were evident only if the receptor had been activated by DAMGO prior to treatment with either H 2 O 2 or EGF, known activators of tyrosine kinase cascades. Furthermore, we found that phosphorylation of the tyrosine residue resulted in a decrease in agonist-mediated efficacy as measured using the GTPγS binding assay.
Tyrosine residue 166 is part of the highly conserved DRY motif found among class A GPCRs.
The DRY motif, located in the second intracellular loop, is important in regulating conformation states of GPCRs and is important for agonist induced G-protein activation (Rovati et al., 2007) . A wide body of research has used mutational analyses to understand the role of this triad sequence. For example, mutation of the aspartic acid (D3.49) of the β 2 adrenergic receptor results in structural instability of the receptor and constitutive activation (Rasmussen et al., 1999) . Likewise, mutation of the aspartic acid (D3.49) of the MOR results in constitutive activation and receptor internalization in the absence of agonist stimulation (Li et al., 2001a; Li et al., 2001b) . A charge-conserving mutation of the arginine residue (R3.50) of the α 1beta-adrenergic receptor led to constitutive activity of the receptor and an increase in binding affinity (Scheer et al., 2000) , whereas mutation of this arginine residue in the α 2alpha adrenergic receptor led to a decrease in binding affinity (Chung et al., 2002) . While much research has investigated the role of the aspartate and arginine residues in the DRY motif, previously there was little understanding of the role of the tyrosine.
We generated a mutant MOR where tyrosine residue 166 was changed to a phenylalanine and found no evidence that this caused constitutive activity. There was no internalization of the receptor in the absence of agonist, and the receptor appeared to internalize normally in the presence of DAMGO. Also, in the GTPγS binding assay, the mutant receptor was not different from the wild type MOR in DAMGOThis article has not been copyedited and formatted. The final version may differ from this version. DAMGO (McLaughlin and Chavkin, 2001 ). The tyrosine and phenylalanine amino acids are structurally similar and this conservative mutation is advantageous when focusing on the effects of phosphorylation, however future studies using alternative substitutions at this site might induce constitutive activity similar to that produced by mutation of the adjacent arginine (Rovati et al., 2007) .
The conclusion that the affinity-purified antibody generated for this study was phosphoselective was based on a series of control experiments. First, the affinity purified MOR-Y166p antibody had a higher affinity for the phosphopeptide than the non-phosphopeptide in the ELISA assay. Also, cotreatment of HEK293 cells that express MOR(Y166F) or untransfected cells with DAMGO and H 2 O 2 showed no increase in immunoreactivity as measured by either western blot or confocal microscopy.
Pretreatment with the MOR antagonist, naloxone, before co-treatment with DAMGO and H 2 O 2 prevented the increase in MOR-Y166p-ir. The apparent molecular weight of the MOR-Y166p-ir was the same as that identified by anti-GFP-ir staining of MOR-GFP expressed by HEK293 cells. Further development of this tool will enable us to extend our research from transfected cells to in vivo models.
Increases in immunoreactivity were not seen in cells that had been treated with DAMGO alone but required co-activation of tyrosine kinases, by treatment with either H 2 O 2 or EGF. This is likely due to a difference in the conformational state of the activated receptor and dissociation of the G-protein that would otherwise occlude the DRY motif. Alternatively, tyrosine phosphorylation of MOR may require β-arrestin recruitment which has been demonstrated to be necessary for Src activation (Luttrell et al., 1999; Walwyn et al., 2007) .
Although the c-terminal tail and 3 rd loop have been implicated in G-protein activation (Johnson and Siderovski, 2007) , it is also believed that agonists can act by changing the conformation of the GPCR 2 nd loop to activate the switch on the G-protein, remove the GDP block required for G-protein activation, or stabilize nucleotide exchange (Rovati et al., 2007; Wacker et al., 2008) . It is therefore possible that the
prior treatment with DAMGO opens the second loop's DRY motif for Src phosphorylation causing subsequent inhibition of G-protein activation. Computational research of agonist-induced conformational states of rhodopsin predicts a disruption of the ionic lock between R3.50 and E6.30 that results in an increase in the distance between R3.50 and Y3.51 (Bhattacharya et al., 2008a) . Indeed, research on the ligand-stabilized conformational states of the β 2-adrenergic receptor has shown that agonist-induced changes include conformational changes of transmembrane helices 3,5 and 6 and breaking of the ionic lock between R3.50 and E6.30. Notably, when comparing agonists, it was found that while all agonists tested were able to induce transmembrane conformational changes, there was a difference in disruption of the ionic lock. Treatment with the full agonist, norepinephrine, was able to induce disruption of the ionic lock whereas treatment with catechol, a weak agonist, was not able to break the ionic lock (Bhattacharya et al., 2008b) . In our experiments robust phosphorylation of MOR-Y166 was seen when we co-treated the cells with DAMGO, a full agonist, and H 2 O 2 or EGF. In the future it would be interesting to compare this response with co-treatment with a weak or partial agonist.
We found that co-treatment of cells with DAMGO and EGF resulted in a significant increase in activation of the non-receptor tyrosine kinase, Src. We also found that pharmacological inhibition of Src blocked DAMGO and H 2 O 2 induced increases in MOR-Y166p-ir. It is known that activation of both the EGFR and MOR increase Src activity (Walwyn et al., 2007) . However, treatment with DAMGO or EGF alone was not able to increase MOR-Y166p-ir, despite the ability of both agonists to lead to a significant increase in Src activation. These results suggest that activation of both pathways results in a robust increase in Src activity and that this combined stimulus is needed for phosphorylation of MOR-Y166 to occur. Previous reports have also shown that in some cases activation of both GPCR and RTK pathways are needed for full stimulation of an effector (Wetzker and Böhmer, 2003) . For example, activation of mitogen-activated protein kinase (MAPK) by the Bradykinin (B2) receptor requires both PKC activation and transactivation of the EGFR (Adomeit et al., 1999) . Also, MOR-mediated activation of extracellular signal-regulated kinase (ERK1/2) by DAMGO in cortical astrocytes also requires transactivation of the
EGFR (Belcheva et al., 2003) . Our results may represent another example of multiple input coordinated signal transduction.
In order to better understand the functional implications of phosphorylation of MOR-Y166, we used the GTPγS binding assay. Studies have shown the DRY motif to be important for regulating Gprotein coupling and activation, and previous studies have shown this tyrosine phosphorylation event to be important for regulating receptor efficacy (Rovati et al., 2007; McLaughlin and Chavkin, 2001) . First, we found that pretreating the membranes with DAMGO resulted in a significant decrease in subsequent DAMGO induced G-protein activation. It is well known that agonist treatment of GPCRs results in desensitization and internalization of the receptor and a reduction in further G-protein activation. We found that co-treatment of membranes with DAMGO and EGF, a stimulus that results in tyrosine phosphorylation at residue 166, resulted in a complete obstruction of GTPγS binding with an Emax that was significantly less than the vehicle control and the DAMGO treated group. This result suggests that phosphorylation of MOR-Y166 results in a decrease in agonist efficacy, and it is consistent with the hypothesis that dephosphorylation of this residue results in an increase in agonist efficacy (McLaughlin and Chavkin, 2001 ).
Interestingly, we found that treatment of membranes with EGF alone resulted in a decrease in agonist-mediated G-protein activation that was comparable to the DAMGO treated group. This result is consistent with research showing that activation of receptor tyrosine kinase cascades transregulate GPCRs (Delcourt et al., 2007) . It has been shown that activation of the EGFR in HEK293 cells results in phosphorylation and activation of GRK2. Activation of GRK2 then promotes internalization of opioid receptors and phosphorylation of DOR at the GRK phosphorylation site (Chen et al., 2008) . Our results complement these studies by suggesting that activation of EGFR leads to a reduction in G-protein coupling. It is notable that the decrease in G-protein binding after EGF treatment was not seen in the mutant receptor, MOR(Y166F).
In summary, we generated and characterized an antibody that can selectively detect phosphorylation of tyrosine 166 of the mu opioid receptor. Our data suggests that agonist activation of One-way ANOVA, p < 0.0001, with a Tukey's Multiple Comparison post-hoc. ***, p < 0.0001 when compared to the vehicle control. ✝✝✝, p < 0.0001 when compared to the DAMGO treated group. ANOVA, p < 0.01, with a one-sample t test. *, p < 0.05, **, p < 0.01 when compared to the vehicle control. Pharmacological data for DAMGO-stimulated GTPγS binding was collected on membranes taken from HEK cells stably transfected with either wild type MOR (MOR) or the MOR mutant Y166F (Y166F). GTPγS binding was measured and analyzed as described under Materials and Methods. Results represent the means ± S.E.M. of 4-8 independent experiments performed in triplicate. Data were analyzed by One-way ANOVA followed by Tukey's Post-Hoc, *, P < 0.05, *** P < 0.001, # P < 0.05 for DAMGO vs. DAMGO+EGF. EC 50 values were determined from non-linear regression analysis (Prism v4.0).
